Compare · BIO vs RVTY
BIO vs RVTY
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $10.97B, about 1.4x BIO ($7.88B).
- Over the past year, BIO is up 29.0% and RVTY is up 8.0% - BIO leads by 21.0 points.
- RVTY has hit the wire 2 times in the past 4 weeks while BIO has been quiet.
- RVTY has more recent analyst coverage (19 ratings vs 12 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- Revvity Inc.
- Price
- $291.34-0.99%
- $100.33+1.92%
- Market cap
- $7.88B
- $10.97B
- 1M return
- +13.28%
- +1.48%
- 1Y return
- +29.01%
- +8.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 1980
- News (4w)
- 0
- 2
- Recent ratings
- 12
- 19
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest BIO
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)